Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

10 results about "Nitazoxanide" patented technology

This medication is used to treat diarrhea caused by certain parasite infections of the intestines (Cryptosporidium parvum and Giardia lamblia)..

Use of an aminonitrothiazole derivative in preparing a drug for preventing and treating viral infections and related diseases caused by them

The present invention provides an aminonitrothiazole derivative for use in the preparation of a drug for preventing and treating viral infections and related diseases caused thereto, and belongs to the field of pharmaceuticals. The structure of the aminonitrothiazole derivative is shown in Formula I. Experimental results show that the compound can effectively inhibit the activity of respiratory syncytial virus, enterovirus 71, and the new coronavirus, and the inhibitory effect is better than that of the positive controls nitazoxanide and lauric acid. The compound provided by the present invention can be used to prepare a drug for preventing and / or treating viral infections, and can be used to prepare a drug for preventing and / or treating related diseases caused by viruses, and has broad application prospects.
Owner:CHENGDU BIOBEL BIOTECHNOLOGY CO LTD

Use of a nitrothiazole derivative for the preparation of an antibacterial agent for inhibiting helicobacter pylori

The application provides a use of a nitrothiazole derivative in preparation of an antibacterial agent for inhibiting helicobacter pylori, and belongs to the field of pharmacy.The structure of the amino nitrothiazole derivative is shown as formula I.The experimental results show that the compound can effectively inhibit the growth of helicobacter pylori, and the inhibiting effect is better than that of control compounds nitazoxanide and lauric acid; the compound can effectively treat mice infected with helicobacter pylori, clear helicobacter pylori in the stomach and reduce the inflammatory response of the stomach tissue, and the treatment effect is better than that of control compounds nitazoxanide and lauric acid.The compound provided by the application can be used for preparing the antibacterial agent for inhibiting helicobacter pylori, and can be used for preparing a medicine for preventing and / or treating helicobacter pylori infection and related diseases caused by the helicobacter pylori, and has a wide application prospect.
Owner:CHENGDU BIOBEL BIOTECHNOLOGY CO LTD

Nanometer drug loading system loaded with nitazoxanide as well as preparation method and application of nanometer drug loading system

The invention relates to a nano drug delivery system loaded with nitazoxanide as well as a preparation method and application of the nano drug delivery system, and belongs to the technical field of pharmaceutical preparations. The nano drug delivery system is prepared by loading nitazoxanide on a metal organic framework ZIF-90 nano material through a simple and rapid method. The nano drug delivery system constructed by the invention can effectively improve the solubility and stability of nitazoxanide, and realizes the enrichment of drugs in tumor cell mitochondria by virtue of the mitochondrial targeting characteristic of the ZIF-90 material. The system can intelligently release drugs under the acidic and high ATP conditions of a tumor microenvironment, not only utilizes the metabolic reprogramming effect induced by nitazoxanide, but also synergistically enhances the anti-tumor effect in cooperation with the Zn < 2 + >-triggered oxidative stress disorder dual mechanism, and provides a new strategy for solving the problems of low bioavailability, poor targeting property and the like in clinical application of nitazoxanide.
Owner:XINXIANG MEDICAL UNIV

A composition for the treatment of liver diseases

PendingDE102024110176A1Organic active ingredientsDigestive systemAnthelmintic drugUncoupling Agents
The present invention relates to a composition for use in a method of treating a liver disease, preferably metabolic dysfunction-associated steatohepatitis (MASH). The composition comprises: • An effective amount of at least one saponin active ingredient (preferably ginsenoside or diosgenin) • And / or an effective amount of at least one anthelmintic (preferably niclosamide or nitazoxanide) • And / or an effective amount of at least one mitochondrial uncoupler.
Owner:RAINCASTLE BIO LTD

A potential genotoxic impurity in a morpholine nitazoxanide raw material and formulations thereof, and methods of making and using the same

The present application relates to the technical field of medicine, in particular to a potential genotoxic impurity in a morpholine nitroimidazole raw material and preparation and a preparation method and application thereof.The potential genotoxic impurity is 2-methyl-5-nitro-1-nitrosoimidazole.A new structure compound 2-methyl-5-nitro-1-nitrosoimidazole of diazoles is found in the synthesis process of the morpholine nitroimidazole raw material for the first time.The compound is identified as a potential genotoxic impurity because of containing a nitrosamine warning structure.A method for analyzing the potential genotoxic impurity 2-methyl-5-nitro-1-nitrosoimidazole by using ultra-high performance liquid chromatography-mass spectrometry is established for the first time, which is of great significance to the quality control of the morpholine nitroimidazole raw material and preparation.The detection method provides a reference for the quality evaluation of other starting materials, intermediates and raw materials that can produce 2-methyl-5-nitro-1-nitrosoimidazole.
Owner:SHANDONG INST FOR FOOD & DRUG CONTROL +1

A composition comprising a saponin and / or an anthelmintic and / or a mitochondrial uncoupler for the treatment of liver disease

PCT designated stageWO2025215232A1Organic active ingredientsDigestive systemPhysiologyUncoupling Agents
The present invention pertains to a composition for use in a method of treating a liver disease, preferably metabolic dysfunction-associated steatohepatitis (MASH), the composition comprising an effective amount of at least one saponin agent, preferably ginsenoside or diosgenin, and / or an effective amount of at least one anthelmintic agent, preferably niclosamide or nitazoxanide and / or an effective amount of at least one mitochondrial uncoupling agent.
Owner:RAINCASTLE BIO LTD

A rapid detection of bacterial energy metabolism kit and its preparation method and application

The application discloses a kit for rapidly detecting bacterial energy metabolism and a preparation method and application thereof, and belongs to the technical field of microorganism analysis, drug screening and detection. The kit comprises reaction premixed powder, anaerobic reaction liquid and optional positive control; the reaction premixed powder comprises the following components in parts by weight: 1 part of benzyl viologen; 0.43-0.64 parts of sodium pyruvate; 0.054-0.082 parts of coenzyme A; 0.037-0.055 parts of MgCl2.7H2O; the anaerobic reaction liquid is a buffer solution containing sodium sulfide-9 hydrate; and the positive control is nitazoxanide or glychalcone A. The application further discloses a preparation method and application of the kit, and the application comprises the following steps: rapidly detecting bacterial energy metabolism activity; and / or screening substances for inhibiting bacterial energy metabolism. The kit can rapidly, sensitively and at low cost evaluate the physiological activity of bacteria, and can also be used for rapidly screening and evaluating anaerobic microorganism energy metabolism inhibitors.
Owner:CHENGDU MEDICAL COLLEGE

Use of nitazoxanide and pharmaceutically acceptable salt thereof in preparation of Anti-adamantinomatous craniopharyngioma drug

The present disclosure relates to the technical field of medicines, and in particular relates to the use of nitazoxanide and a pharmaceutically acceptable salt thereof in the preparation of an anti-adamantinomatous craniopharyngioma drug. Provided in the present disclosure is the use of nitazoxanide and a pharmaceutically acceptable salt thereof in the preparation of an anti-adamantinomatous craniopharyngioma drug. Nitazoxanide and the pharmaceutically acceptable salt thereof are capable of inhibiting the proliferation and colony formation ability of adamantinomatous craniopharyngioma organoids by means of promoting the degradation of a β-catenin, are targeted drugs capable of effectively blocking an activation pathway of the β-catenin, have good therapeutic efficacy and application prospects for adamantinomatous craniopharyngioma, and solve the problem of lack of targeted drugs for treating adamantinomatous craniopharyngioma.
Owner:BEIJING SANBO BRAIN HOSPITAL